Brentuximab Vedotin in Combination With CHEP in Patient With PTCL
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with
Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)